### MAR 9 2006

## Attachment 4 510(k) Summary Statement

#### I. General Information

Submitter: Lumenis, Inc.

2400 Condensa Street

Santa Clara, California, U. S. A.

95051-0901

Contact Persons: Conni

Connie Hoy

Summary Preparation Date:

February 5, 2006

II. Names

Device Names: Family of Selecta Ophthalmic Laser Systems, Delivery

Device and Accessories

Selecta 1064 Ophthalmic Laser System Selecta SLT Ophthalmic Laser System Selecta Duo Ophthalmic Laser System Selecta Duet Ophthalmic Laser System Selecta Trio Ophthalmic laser System

KO60338

LaserLink S

Primary Classification Name: 79, General and Plastic Surgery Panel

GEX, Laser powered surgical instrument

#### III. Predicate Devices

Lumenis Family of Selecta Ophthalmic Laser Systems K051944

#### IV. Product Description

The Lumenis Selecta is a fully integrated flash lamp pumped, solid state, Nd:YAG ophthalmic surgical laser system intended for use in the treatment of ocular pathology and for use as a diagnostic slit lamp.

The Selecta Family of Ophthalmic Lasers, Delivery Device and Accessories are comprised of the following configurations:

Selecta 1064®— a Nd:YAG laser providing Q-switched laser pulses at a wavelength of 1064nm for use in photodisruption of ocular tissue (posterior capsulotomy, papillary membranectomy, iridotomy). The 1064nm treatment beam delivers a 4 nsec, 0.3-10mJ adjustable and selectable single, double or triple pulse of energy. It is conditioned through beam shaping optics to generate a photodisruption micro pulse of plasma at a precision adjustable location relative to the visual focal plane (located at slit lamp center of rotation) and along the slit lamp objective lens axis. A twin aiming beam is also focused by the slit lamp objective to a converging 20μm spot located at the focal point of the lens. The

focal point of photodisruption is adjustable 0-350µm in the posterior direction by the physician relative to this convergence of the twin aiming beams.

Selecta SLT® — a Nd:YAG laser providing Q-switched frequency doubled pulses at a wavelength of 532nm for use in selective laser trabeculoplasty. The treatment beam delivers a 4nsec, 0.1-2mJ adjustable single pulse of energy. The aiming and treatment beams are coaxial with each other and focused by the slit lamp objective to a 400 µm spot at the focal point of the lens.

Selecta Duet® — a Nd:YAG laser providing Q-switched laser pulses at a wavelength of 1064 nanometers for use in photodisruption or Q-switched frequency doubled pulses at a wavelength of 532nm for use in selective laser trabeculoplasty, depending upon the mode selected. The Selecta Duo contains two aiming beam modules that produce a single beam for the 532nm mode and a dual beam for the 1064nm mode, respectively.

LaserLink S — a laser slit lamp delivery adaptor that may be coupled to each of the above Selecta models and connected to a currently cleared Lumenis 532nm photocoagulator to allow the physician to use the Selecta slit lamp to deliver 532nm continuous wave laser energy for photocoagulation.

Selecta Duo - a Selecta 1064® and LaserLink S slit lamp delivery device with a currently cleared Lumenis 532nm photocoagulator

Selecta Trio - a Selecta Duet and LaserLink S slit lamp delivery device with a currently cleared Lumenis 532nm photocoagulator

Selecta SLT and LaserLink S with a currently cleared Lumenis 532nm photocoagulator

#### $\mathbf{V}_{\star}$ Indications for Use

Selecta 1064: photodisruption of ocular tissue using light energy emitted by a Nd:YAG laser, including discission of the posterior capsule of the eye (posterior capsulotomy), and discission of pupillary membranes (pupillary membranectomy) in aphakic and pseudophakic patients, and iridotomy/iridectomy

Selecta SLT:

selective laser trabeculoplasty

Selecta Duet:

photodisruption of ocular tissue using light energy emitted by a Nd:YAG laser, including discission of the posterior capsule of the eye (posterior capsulotomy), and discission of pupillary membranes (pupillary membranectomy) in aphakic and pseudophakic patients, and iridotomy/iridectomy; and

selective laser trabeculoplasty

LaserLink S: laser delivery system for use by an ophthalmologist in the treatment of ocular tissue;

> laser delivery system indicated for use for a variety of ophthalmic uses, including the indications specified in the laser operator manual. Refer to the laser operator manual, Indications for Use section.

The Selecta 1064, Selecta SLT and Selecta Duet Ophthalmic Lasers are also intended for use as a diagnostic slit lamp, specifically,

An AC-powered slit lamp biomicroscope intended for use in eye examination of the anterior segment, from the cornea epithelium to the posterior capsule. It is used to aid in the diagnosis of diseases or trauma which affects the structural properties of the anterior segment.

Selecta Duo: same indications for use as a Selecta 1064® and LaserLink S slit lamp

delivery device with a currently cleared Lumenis 532nm

photocoagulator

Selecta Trio: same indications for use as a Selecta Duet and LaserLink S slit lamp

delivery device with a currently cleared Lumenis 532nm

photocoagulator

#### VI. Rationale for Substantial Equivalence

The devices in this submission are identical to the predicate devices. The purpose of this 510(K) is for a name change only with no changes to the device or the indications for use.

#### VII. Performance Data

None

#### VIII. Conclusion

The Family of Selecta Ophthalmic Laser Systems, Delivery Device and Accessories are substantially equivalent to the predicate laser devices, delivery systems and accessories. The Family of Selecta Ophthalmic Laser Systems, Delivery Device and Accessories share the same intended use, indications for use, and technological characteristics as the predicate laser systems.

Food and Drug Administration



9200 Corporate Boulevard
Rockville MD 20850

MAR 9 2006

Lumenis, Inc. c/o Ms. Connie Hoy Global Director of Regulatory Affairs and Quality Assurance 2400 Condensa Street Santa Clara, California 95051

Re: K060338

Trade/Device Name: Family of Selecta Laser Systems (Selecta 1064, and Selecta Duet,

Selecta Duo, Selecta Trio and Delivery Device (LaserLink S) and

Accessories

Regulation Number: 21 CFR 878.4810

Regulation Name: Laser surgical instrument for use in general and plastic surgery and in-

dermatology

Regulatory Class: II Product Code: GEX Dated: February 5, 2006 Received: February 10, 2006

Dear Ms. Hoy:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PNL), a may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must

comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <a href="http://www.fda.gov/cdrh/dsma/dsmamain.html">http://www.fda.gov/cdrh/dsma/dsmamain.html</a>

Sincerely yours,

Mark N. Melkerson

Acting Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

## Attachment 2 Indications for Use Statement as Requested by FDA

K060338

510(K) Number (if Known):

	Duo, Selecta Trio and Delivery Device (LaserLink S) and Accessories
Indications for Use:	
Selecta 1064:	photodisruption of ocular tissue using light energy emitted by a Nd:YAG laser, including discission of the posterior capsule of the eye (posterior capsulotomy), and discission of pupillary membranes (pupillary membranectomy) in aphakic and pseudophakic patients, and iridotomy/iridectomy
Selecta SLT:	selective laser trabeculoplasty
Selecta Duet:	photodisruption of ocular tissue using light energy emitted by a Nd:YAG laser, including discission of the posterior capsule of the eye (posterior capsulotomy), and discission of pupillary membranes (pupillary membranectomy) in aphakic and pseudophakic patients, and iridotomy/iridectomy; and
	selective laser trabeculoplasty
LaserLink S:	laser delivery system for use by an ophthalmologist in the treatment of ocular tissue;
	laser delivery system indicated for use for a variety of ophthalmic uses, including the indications specified in the laser operator manual. Refer to the laser operator manual, Indications for Use section.
(PLEASE DO NOT W	RITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Con	currence of CDRH, Office of Device Evaluation (ODE)
	(Division Sign-Off)
	Division of General, Restorative,
	and Neurological Devices
	510(k) Number K060338
Prescription Use:X (Per 21 CFR 801.109) Optional Format	<del></del>

# Attachment 2, Continued Indications for Use Statement as Requested by FDA

Indications for Use:	Duo, Selecta Trio) and Delivery Device (LaserLink S) and Accessories
	64, Selecta SLT and Selecta Duet Ophthalmic Lasers are also intended gnostic slit lamp, specifically,
	An AC-powered slit lamp biomicroscope intended for use in eye examination of the anterior segment, from the cornea epithelium to the posterior capsule. It is used to aid in the diagnosis of diseases or trauma which affects the structural properties of the anterior segment.
Selecta Duo:	same indications for use as a Selecta 1064® and LaserLink S slit lamp delivery device with a currently cleared Lumenis 532nm photocoagulator
Selecta Trio:	same indications for use as a Selecta Duet and LaserLink S slit lamp delivery device with a currently cleared Lumenis 532nm photocoagulator
(PLEASE DO	O NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
	(Division Sign-Off) Division of General, Restorative, and Neurological Devices
	510(k) Number <u>K060338</u>
Prescription Use: (Per 21 CFR 801.109)	_X OR Over-The-Counter Use: